Open AccessEffect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
Author(s) -
Kitada Munehiro,
Ogura Yoshio,
Nitta Kyoko,
Fujii Mizue,
Kanasaki Keizo,
Konishi Kazunori,
Iida Yasuo,
Nakagawa Atsushi,
Koya Daisuke
Publication year - 2019
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12917
Subject(s) - medicine , glycated hemoglobin , endocrinology , dipeptidyl peptidase 4 , diabetes mellitus , type 2 diabetes , creatinine , renal function , dipeptidyl peptidase , diabetic nephropathy , type 2 diabetes mellitus , chemistry , enzyme , biochemistry
Aims/Introduction The objective of the present study was to elucidate the effect of switching to teneligliptin from other dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors on glucose control and renoprotection in type 2 diabetes mellitus patients with diabetic kidney disease. Materials and Methods The present study was a single‐arm, open‐label, observational study. A total of 23 patients, who had urinary albumin/creatinine ratios ( UACR ) ≥30 mg/ gC r in their first urine in the early morning, and received other DPP ‐4 inhibitors and renin‐angiotensin system inhibitors, switched to teneligliptin 20 mg/day. After switching to teneligliptin for 24 weeks, we evaluated changes in glycated hemoglobin (HbA1c), fasting plasma glucose levels, plasma DPP ‐4 activity and UACR . Results HbA1c, fasting plasma glucose and UACR values showed no significant change after 24 weeks compared with baseline. However, plasma DPP ‐4 activity was significantly reduced after 24 weeks (0.57 ± 0.26 nmol/min/ mL , P = 0.012, vs baseline), compared with baseline (1.49 ± 1.73 nmol/min/ mL ), and there was a positive relationship between the change rate of plasma DPP ‐4 activity (Δ% DPP ‐4) for 24 weeks and the levels of plasma DPP ‐4 activity ( r = −0.5997, P = 0.0025) and fasting plasma glucose ( r = −0.4235, P = 0.0440) at baseline. Additionally, the Δ% DPP ‐4 for 24 weeks was significantly correlated to the change rate of UACR ( r = 0.556, P = 0.0059). However, there was no relationship between Δ% DPP ‐4 and ΔHbA1c (amount of HbA1c change). Conclusions Switching to teneligliptin from other DPP ‐4 inhibitors for 24 weeks reduces plasma DPP ‐4 activity, which is associated with a reduction in albuminuria, independent of the change in glucose levels, in type 2 diabetes mellitus patients with diabetic kidney disease.